A new analysis method that uses fetal DNA extracted from the mother's blood is designed to non-invasively reach a prenatal diagnosis of genetic disorders in a child. A task force of the Hahn Schickard Society for Applied Research is an active part of the "ANGELab" project and co-developed this diagnostic procedure.
The project name "ANGELab" is an acronym for "A new genetic laboratory for non-invasive prenatal diagnosis". In this interview with MEDICA-tradefair.com, Dr. Nadine Borst explains how the non-invasive, rapid test works.
What is the reason behind the "ANGELab" EU project?
Dr. Nadine Borst: The miscarriage risk of an amniocentesis – an invasive diagnostic procedure – is about 0.5 percent. Our objective was to develop new non-invasive diagnostic techniques that do not pose a risk to the mother or the child. ...
Read the complete interview with Dr. Nadine Borst at MEDICA-tradefair!